

Contact: Dean Draznin Communications 641-472-2257, dean@drazninpr.com

Unique Sugar Improves Energy, Pain and Quality of Life in Fibromyalgia and Chronic Fatigue Patients!

New Study on D-ribose published in *Journal of Alternative and Complementary Medicine*

Minneapolis, MN (Nov 13, 2006) – Following the recent announcement by the Centers for Disease Control and Prevention that Chronic Fatigue Syndrome (CFS) is a major public health concern, the *Journal of Alternative and Complementary Medicine* (12:9, 2006, 35-40) published a study unveiling a new and promising treatment for CFS and fibromyalgia (FMS).

The research conducted by Jacob Teitelbaum, MD, Medical Director of the Fibromyalgia and Fatigue Centers, Inc., and author of two books on the topic, found a full two-thirds of his patients reported improvement of their symptoms in the first 12 days following a course of CORvalen® treatment. The average improvement in energy was 45%, and quality of life improved an average of 30%. Patients reported less muscle soreness and stiffness, better ability to overcome fatigue, as well as simply feeling better.

CORvalen®, developed by Bioenergy Life Science, contains D-ribose, a unique sugar made by the body to synthesize many important compounds, including DNA, RNA, and most importantly, Adenosine Triphosphate (ATP), the ‘energy currency’ of the cells. According to some experts, FMS and CFS patients suffer from cellular energy depletion. CORvalen® D-ribose provides metabolic support to accelerate cellular energy recovery and normal cellular functioning.

According to Teitelbaum, principal researcher in the open label feasibility study, the findings of the study are significant. “The results are outstanding for a single entity product,” he says. “More specifically, the research helped us pinpoint the energy-building benefit of CORvalen® and how it substantially reduces the debilitating symptoms of these conditions. I think this study, and follow-up studies now underway, will make CORvalen® one of the most important new nutrients evaluated over the next few years.”

Bob Baurys, founder and CEO of the Fibromyalgia and Fatigue Centers, Inc. says that CORvalen® is a standard therapy for patients with FMS and CFS. “The Fibromyalgia and Fatigue Centers around the country were founded on the principle that these patients need specialized, focused treatments for their complex medical conditions in order to see improvement,” he explains.

Baurys, himself a fibromyalgia patient, knows first-hand what it’s like to struggle with the disease. “Our six-step integrated treatment program is designed to not only help relieve the patient’s symptoms, but also to address the underlying cause of those symptoms,” he says. “One of those six steps is promoting cellular energy, and we have had success doing that with CORvalen®, an all-natural dietary supplement.”

The Fibromyalgia and Fatigue Centers are playing an important role in the research into these mysterious and frequently debilitating conditions—reviewing the latest science, examining complex case studies and sharing information through the FFC physician network. Centers are now open in Amarillo, TX, Atlanta, Boston, Cleveland, Dallas, Denver, Detroit, Ft. Worth, Houston, Las Vegas, Los Angeles, Norwalk, CT, Philadelphia, Pittsburgh, Portland, Salt Lake City and Seattle.

At Expo West, visit Bioenergy at booth #1226. Bioenergy, Inc. is a privately held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-ribose in health and wellness. Bioenergy's clear mission is to develop products that increase the quality of its customers' lives by improving their metabolic health. Bioenergy Life Science, Inc., its subsidiary, markets ribose-based products to the functional food and clinical nutrition markets. Bioenergy Life Science products include Bioenergy RIBOSE™, a functional ingredient in the active lifestyle market; as well as CORvalen® and CORvalenM®, clinical nutrition products giving metabolic support to patients with heart and muscle disease.

###